ETS's Praxis program, the leading provider of teacher licensure assessments, welcomes the adoption of Praxis as an approved ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

The early clinical evidence suggested ulixacaltamide could provide meaningful improvement over current therapies for ET ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...

Praxis Precision Medicines has recorded a midphase win in epilepsy, linking the high dose of PRAX-628 to a 100% complete response rate to clear the path for a larger study in the second half of the ...

Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.

Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...

A committee of outside clinical trial observers has recommended that Praxis Precision Medicines stop testing its experimental treatment for essential tremor after an interim analysis of one study ...

It’s been a tough year of layoffs and pipeline culls for Praxis Precision Medicines, but the biotech is ending 2022 on a positive note courtesy of a collaboration with UCB to develop a potential first ...